The study of X-chromosome inactivation patterns (XCIPs) to determine tumor clonality was established by Fialkow using G6PD protein isoenzymes but was limited by the low frequency of heterozygotes. Analysis was extended to most females with the demonstration of differential DNA methylation patterns on active and inactive X-chromosome alleles and uses Southern blotting or PCR of either restriction enzyme polymorphisms, eg PGK, HPRT, or variable number tandem repeat sequences, eg M27␤, HUMARA. More recently RNA polymorphisms have been reported enabling direct analysis of expressed transcripts from the two alleles. Interpretation of clonality requires knowledge of an individual's constitutive XCIP as skewing (Ͼ75% expression of one allele) occurs in a significant proportion of hematologically normal females, probably due to the stem cell pool size at the time of Lyonization. Furthermore, acquired skewing occurs with increasing age. For myeloid disorders in the young, T lymphocytes serve as a suitable control XCIP, but interpretation of imbalanced XCIPs in the elderly can be difficult. In AML, XCIPs at presentation are consistent with a clonal disorder whereas in remission comparison with normal controls suggests that true clonal remission is infrequent. Sequential analysis of samples may be helpful in some patients in order to determine evolving clonal populations. Keywords: X-chromosome inactivation pattern; methylation; skewing; clonal remission
Techniques
The pioneering work of Beutler 1 and Fialkow 2 laid the foundations for the widespread use of X-chromosome inactivation patterns (XCIPs) to determine the clonal origin of a tumor sample, and this technique has now been applied to a variety of hematological disorders. Early studies were limited to small sample numbers by the low frequency of G6PD isoenzyme heterozygosity in most racial groups. It was not until 20 years after the first application of XCIPs to tumors of hematological tissues 3, 4 that Vogelstein and colleagues 5 reported two Xlinked genes that were polymorphic at the DNA level and were sufficiently informative to allow study of approximately 50% of females using Southern blotting. The key to their technique was the demonstration that the active and inactive Xchromosomes could be distinguished by their methylation patterns. A preliminary restriction enzyme digest identified those females who were heterozygous for the polymorphism, ie either BglI or BstXI for the phosphoglycerate kinase (PGK) gene or BamHI for the hypoxanthine phosphoribosyl transferase (HPRT) gene, but it could not determine the expression of the two alleles as dictated by the random inactivation of one allele in each cell. There were, however, a number of cytosine residues which were differentially methylated on active and inactive alleles and could be discriminated using methylationsensitive enzymes such as HpaII or HhaI. After digestion of all unmethylated alleles to a size too small to be detected by the probe, the intensity of the bands from the remaining methylated alleles therefore reflected the relative expression of the two alleles. A further highly polymorphic variable number tandem repeat sequence (VNTR) was described at the DXS255 locus detected by the M27␤ probe, 6 the only difference being that methylation-sensitive enzyme digestion reduced the unmethylated alleles by approximately 500 bp in size and they were therefore still visible and quantifiable. 7 Taken together approximately 90% of females are informative for one or more of these loci and comparative results show a good correlation between the M27␤ and HPRT or PGK probes, r = 0.89. 7 Nevertheless, the large amount of DNA required for Southern blotting has always been a disadvantage and in general it has been replaced by the study of X-linked genes which are amenable to PCR analysis, ie where the polymorphism and differential methylation sites are situated close together. Several genes are suitable but most studies have been carried out using either PGK 8 or the highly polymorphic VNTR in the human androgen receptor (HUMARA) gene.
Since PCR does not maintain methylation of the alleles, the DNA is first digested with the methylation-sensitive enzyme so that amplification is performed only on the uncut, ie methylated alleles. Where necessary the PCR products are then digested with the relevant restriction enzyme to reveal the polymorphism, eg for the PGK gene, before separation of the alleles by polyacrylamide gel electrophoresis. Provided that technical artefacts are taken into account, for example, the preferential amplification of shorter alleles with VNTRs or heteroduplex formation of mismatched alleles in RFLPs which interferes with restriction enzyme digestion, quantifiable results can be obtained which correlate well with those from Southern blotting. In a study comparing XCIP values from the HUMARA-HpaII assay with Southern blotting, the correlation coefficient was 0.97. 10 The speed and ease of analysis, in particular for small DNA samples such as purified populations of cells or colonies grown in culture, have ensured extensive use of this technology.
Problems relating to clonal analysis of DNA samples have usually arisen because of the complex methylation patterns that are sometimes seen, for example, hypermethylation of both alleles has been reported in leukemic samples using Southern blotting with the M27␤ probe 7, 11 and PCR-HUM-ARA analysis. 10 Recently X-linked polymorphisms have been described in RNA which avoid this problem since direct analysis of transcribed alleles can be studied, provided that the gene is expressed in the tissue of interest. Approximately 68% of females are informative for one or more of the three single base substitutions described to date which are in housekeeping genes with widespread tissue expression, G6PD (but different from the A/A− isoenzyme), 12 iduronate-2-sulphatase (IDS) 13 and the palmitoylated membrane protein p55. 14 After reverse transcription of the RNA, samples can be analyzed by several methods: PCR plus allele-specific oligonucleotide hybridization, 15 PCR using a mismatch primer to introduce a 118 restriction site in one allele only 16 or PCR plus the ligase detection reaction with specific primers to distinguish the two alleles.
14 Results from our laboratory show good correlation between values obtained using a mismatch primer for the IDS gene and PCR-based DNA results, r = 0.98, provided that the number of cycles is limited to reduce heteroduplex formation (Harrison, Gale and Linch, unpublished observation). Nevertheless, although analysis of RNA is advantageous because it removes the problems associated with methylation and can be applied to all tissues expressing the gene, other factors such as sample purity become extremely important. In the analysis of hematological samples, for example, red cells contaminating neutrophil preparations or platelets present in T lymphocyte preparations, will not interfere with DNA-based analysis but will influence RNA results as the transcript will still be present in these cells.
With currently known polymorphisms, clonal analysis can now be applied to most females using either DNA or RNA techniques. However, because of the inherent complexity of each method, wherever possible it is desirable to confirm results using two techniques.
Interpretation of XCIPS
Studies of malignant hematological disorders have brought into focus the question of how an XCIP should be interpreted and what a clonal pattern might mean. Since X-chromosome inactivation is a random process it was thought that a normal polyclonal pattern should show approximately 50% expression of each allele; patterns that diverged from this and were imbalanced or skewed with Ͼ75% expression of one allele were considered to demonstrate oligoclonal or monoclonal hemopoiesis. 5 However, more detailed analyses have indicated that there is considerable variation in XCIPs from hemopoietic cells of hematologically normal females and a significant proportion (20-25%) have an imbalanced or skewed pattern. [17] [18] [19] It is probable that this relates to the size of the primordial stem cell pool committed to hemopoiesis at the time of X-inactivation. If eight hemopoietic stem cells are present at the time of random inactivation it will create a population where 18% of the females have a skewed XCIP, close to the observed value, and a small number of females (Ͻ4%) will have even more pronounced skewing with Ͼ90% expression of one allele. 20 An apparently 'clonal' XCIP cannot therefore be interpreted on its own as evidence for clonal hemopoiesis as it may simply reflect the constitutive Lyonization pattern for the hemopoietic cells of that individual. Conversely, a balanced XCIP in an individual is strongly suggestive of polyclonal hemopoiesis. Interpretation of an XCIP therefore requires a control XCIP for comparison. However, this has presented a conundrum as to a suitable tissue since, unlike solid tumors where non-malignant tissue of the same type can usually be obtained, myeloid cells from a patient pre-dating the transforming event are rarely available. Skin and cultured fibroblasts may not be appropriate as controls in some individuals as a number of studies have indicated that XCIPs are tissue-specific, probably because the progenitor cell pool size at the time of Lyonization varies for different tissues. [21] [22] [23] For disorders such as acute myeloid leukemia (AML), T lymphocytes are a suitable comparative control: they are not involved in the leukemic clone, originate from the same pluripotent stem cell as myeloid cells 24 and, at least in young individuals, show the same constitutive XCIP. 25 However, in other disorders, in order to determine whether they are clonal or whether a specific cell lineage is involved within the clonal process, it may be necessary to use large population studies comparing the distribution of patterns obtained with those from hematologically normal controls. 18 Recent studies have exposed a further difficulty for the interpretation of XCIPs as it has been demonstrated that they can change with age.
19,25,26 Aproximately 40% of hematologically normal females у75 years acquire a skewed XCIP in their myeloid cells and in 33% of elderly females this is extreme with Ͼ90% expression of one allele. 25 These results are not necessarily indicative of a preleukemic phase nor of stem cell depletion, neither myelodysplasia nor idiopathic hemopoietic failure reach such levels, even in the elderly. They may, however, reflect changes in stem cell usage due to symmetric division of some stem cells to two daughter stem cells and others to two terminally committed cells which would lead to gradual loss of some of the original members of the stem cell pool present at the time of X-inactivation and expansion of others to maintain the total number of stem cells. These random, non-pathological shifts in the XCIP may also result from some (small) selective advantage or disadvantage of cells expressing one particular X-chromosome. Whatever the cause of this phenomenon, it has important implications for the interpretation of apparent clonality in diseases of the elderly.
XCIPS and acute myeloid leukemia
Interpretation of XCIPs has played an important role in our understanding of AML. The clonal nature of this disorder has largely been demonstrated by the presence of disease-specific karyotypic abnormalities, 27 and monoclonal or skewed XCIPs are consistent with the predominance of a single clone of cells in the majority of patients. 18 When analysis of AML patients in remission showed that approximately one quarter had an imbalanced pattern 28 it was therefore hypothesized that this represented the return to a preleukemic state, analogous to the return to chronic phase in chronic myeloid leukemia. Furthermore, it was thought that this reflected the multi-step pathogenesis of the disease with cells that were premalignant and apparently clonal but were now able to differentiate to morphologically mature cells and undergo normal growth control. This was of clinical significance as it was anticipated that these patients might show an increased susceptibility to relapse.
However, these results had been analysed without reference to the constitutive Lyonization pattern in hemopoietic cells of these individuals. Follow-up analysis of 10 patients who had skewed XCIPs in their remission bone marrow showed that in nine this could be explained by a constitutively skewed Lyonization pattern, with the same degree of skewing in remission granulocytes and T lymphocytes. 18 In another study of patients with acute promyelocytic leukemia, 29 hematological remission correlated with the disappearance of leukemiaspecific markers in all 13, and in the one patient with a skewed XCIP in her remission bone marrow an identical pattern was observed in T cells and skin. In our study of 77 AML patients and 75 hematologically normal controls no difference was observed between the degree of skewing in the two groups (P Ͻ 0.1), 18 and if patients and controls Ͼ60 years of age are excluded from the analysis there is also no significant difference between the variance of the distribution of XCIPs from the two groups. The overall clinical outcome of the 26 patients with a skewed remission pattern was no different from that expected for unselected patients receiving similar chemotherapy. It would appear therefore that true clonal remission in AML is infrequent, probably Ͻ10% of total. However, some studies have indicated that, where present, it is often associated with trilineage myelodysplasia. 30, 31 XCIP analysis was first used to question the extent of lineage involvement present in AML in 1979 32 and intriguing results since then have suggested that the origin of the disease may be heterogeneous, in particular with reference to age. In the study by Fialkow and colleagues, 33 the clonal pattern in a series of young patients (р43 years) was restricted to cells of the granulocytic lineage, whereas in older patients (61-80 years) the disease appeared to have arisen in a stem cell with multipotent potential. This is of interest in view of the evidence of karyotypic and biologic similarities between de novo AML in the elderly and secondary AML, in particular therapy-related AML or myelodysplasia (MDS), suggesting that AML in the elderly may more commonly represent evolution from a preleukemic, myelodysplastic state. 34 The recent reports showing acquired skewing of XCIPs in elderly females, particularly in myeloid cells, 25 however, indicate that the use of XCIPs to examine this issue requires re-evaluation, and analysis of leukemia-specific markers may provide a more definitive answer to the heterogeneity of lineage involvement.
As yet it is unclear whether a phase of non-symptomatic (and hematologically normal) clonal predominance precedes overt myelodysplasia or leukemia in some or all patients, and, if so, whether we can detect it. Furthermore, interpretation of such results may be influenced by the type of sample studied, for example analysis of peripheral blood cells may not accurately reflect the clonal status of the underlying bone marrow, particularly in situations such as aleukemic leukemia and early or low-risk MDS where the majority of bone marrow cells may not be released into the circulation. The demonstration of a shift in the XCIP of an individual has been used to detect the presence of an evolving clonal population due to disease progression, for example in the demonstration of secondary MDS or AML after high-dose therapy. 35, 36 These patients represent a 'preselected' group as they are already at high risk of relapsing or transforming to a myeloid malignancy due to the treatment they have received, although early warning of a developing clonal disorder may ultimately benefit their treatment as, at present, they have a poor prognosis. Such studies are limited, however, not only by the frequency of constitutionally skewed XCIPs but also by the low sensitivity of the techniques. Minor clonal populations will not be detected on a polyclonal background due to a wide technical variation: in our laboratory we only consider values differing by Ͼ20% expression of one allele to be significantly different, although an underlying trend may be indicated by sequential shifts. For example, in a patient transplanted for relapsed Hodgkin's disease who subsequently presented with AML, we were able to retrospectively detect an emerging myeloid clone at a time when the patient was hematologically normal. 36 At 50 months post-transplant there was no morphological evidence for myelodysplasia in the peripheral blood and the purified granulocyte and T lymphocyte XCIPs were both balanced (mean 36:64% and 58:42% expression of the two alleles, respectively) but just significantly different. The bone marrow harvest sample had a mean XCIP value of 66:34%. On their own these values were not indicative of clonal hemopoiesis as we could not exclude regeneration from a small stem cell pool, and it was only when she presented with AML 7 months later with an XCIP of 0:100% that we could definitively identify the presence of the clone.
The use of XCIP analysis in malignant myeloid disorders has therefore raised fundamental issues regarding the interpretation of clonality of hemopoietic cells although there are still situations which might benefit from the application of this technology. XCIP analysis can, for instance, be used to demonstrate polyclonality in some patients where it is not clear whether a proliferation is clonal.
